Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

4/12/2024
BreakingGenericsGlaucomaPharmaRegulation
Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme
Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme

Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...

4/12/2024
BreakingPharmaRegulationRetina
US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea
US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea

The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. T...

4/12/2024
BreakingDealsIndiaIndustry
US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy
US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy

US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...

4/12/2024
BreakingCataractDealsIndustryPharma
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

4/12/2024
BreakingEmergingEuropeFundingGlaucomaSurgical
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis

Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...

4/12/2024
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate

Ocugen announced April 8 that the US FDA had cleared the company’s investigational new drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy candidate for r...

4/12/2024
BreakingCataractIOLSurgical
Rayner Marks Sale of 5 Millionth RayOne IOL
Rayner Marks Sale of 5 Millionth RayOne IOL

UK-based Rayner reported April 3 that it had sold its 5 millionth RayOne lens and 11 millionth lens made from RayAcryl, Rayner’s proprietary hydrophilic acrylic material. Rayner, founded in 1910, r...

4/5/2024
BreakingClinical TrialPresbyopia
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024

Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative-free, single-use, once-daily ey...

4/5/2024
BreakingRegulation
Viatris, Ocuphire Announce US Launch of Ryzumvi Eye Drops to Reverse Pupil Dilation
Viatris, Ocuphire Announce US Launch of Ryzumvi Eye Drops to Reverse Pupil Dilation

Viatris and Ocuphire Pharma announced April 1 the US launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. The US FDA approved Ryzumvi ...

4/5/2024
BreakingClinical TrialDry Eye
Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye
Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye

Aldeyra Therapeutics on March 28 outlined its new clinical development plan for reproxalap eye drops, with the goal of resubmitting its new drug application (NDA) to the US FDA. The company said it...

4/5/2024
BreakingGlaucomaRegulation
Glaukos’ iDose Gets J-Code for Medical Billing in the US
Glaukos’ iDose Gets J-Code for Medical Billing in the US

The Centers for Medicare and Medicaid Services (CMS) has issued a J-code for Glaukos’ iDose. The billing code takes effect July 1, 2024. iDose TR gained US FDA approval under the 505(b)(2) pathway ...

4/5/2024
BreakingCornealDeals
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts

West Point Optical Group, which operates 86 Pearle Vision clinics in 13 states, announced April 3 that it had reached an agreement with Verséa Ophthalmics to offer Verséa’s Biovance and Biovance 3L...

Past News Stories

4/5/2024
BreakingDigitalIndustryMicroscopesSurgical
Beyeonics Vision Appoints A. Burton Tripathi, PhD, as CEO
Beyeonics Vision Appoints A. Burton Tripathi, PhD, as CEO

Israel’s Beyeonics Vision announced March 28 that it had appointed A. Burton Tripathi, PhD, as its new chief executive officer. Tripathi was formerly CEO of TrueVision 3D Surgical. After Alcon acqu...

4/5/2024
BreakingGlaucomaIndustryPharma
Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer
Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer

France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...

3/29/2024
BreakingDry EyeGlaucomaLaserRevenue
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay

Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...

3/29/2024
BreakingClinical TrialGene TherapyRegulationRetina
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024

Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in...

3/29/2024
BreakingData SecurityRegulation
State Department Offers up to $10 Million for Info on Hackers of Change Healthcare
State Department Offers up to $10 Million for Info on Hackers of Change Healthcare

The US State Department announced March 27 that it was offering a reward of up to $10 million for information on ALPHV BlackCat-linked hackers targeting critical infrastructure in the US. The agenc...

3/29/2024
BreakingPharmaRegulationSurgical
Chambers Retires from US FDA After 36-Plus Years of Ophthalmic Drug Review
Chambers Retires from US FDA After 36-Plus Years of Ophthalmic Drug Review

Wiley Chambers, MD, an ophthalmologist who conducted or supervised the review of ophthalmic drugs at the US FDA for 36 1/2 years, retired from the agency Jan. 13, 2024. The 65-year-old is now servi...

3/29/2024
BreakingCornealDealsRetinaSurgical
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front

ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...

3/29/2024
BreakingDeals
Provectus Licenses from University of Miami a Photodynamic Antimicrobial Treatment with Rose Bengal Sodium
Provectus Licenses from University of Miami a Photodynamic Antimicrobial Treatment with Rose Bengal Sodium

Provectus Biopharmaceuticals announced March 27 that it had entered into an agreement with the University of Miami for an exclusive worldwide license of a photodynamic antimicrobial therapy (PDAT) ...

3/29/2024
BreakingClinical TrialDry Eye
Okyo’s Dry Eye Candidate Hits Multiple Phase II Endpoints, Including Ocular Pain Relief
Okyo’s Dry Eye Candidate Hits Multiple Phase II Endpoints, Including Ocular Pain Relief

London’s Okyo Pharma released additional findings on March 22 from its Phase II trial of topical dry eye candidate OK-101. The company had previously reported statistically significant improvements...

9/8/2023
BreakingCataractEuropeGlaucomaIndiaIndustryMeetingNewsletterRefractiveRetina
2024-2025 Ophthalmic Meetings Calendar
2024-2025 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

3/29/2024
BreakingClinical TrialRegulationRetina
Belite Bio Applies to Japanese Regulators for Clinical Trial of Oral Stargardt Candidate
Belite Bio Applies to Japanese Regulators for Clinical Trial of Oral Stargardt Candidate

Belite Bio announced March 22 that it had applied to Japan’s Pharmaceuticals and Medical Devices Agency for clearance to conduct a clinical trial of tinlarebant, its oral treatment candidate for St...

3/29/2024
BreakingRegulationRetina
US FDA Approves Alexion’s C5 Inhibitor Ultomiris for Adults with NMOSD
US FDA Approves Alexion’s C5 Inhibitor Ultomiris for Adults with NMOSD

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for the treatment of adults with ...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more